173 related articles for article (PubMed ID: 24788789)
1. Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice.
Westwood JA; Potdevin Hunnam TC; Pegram HJ; Hicks RJ; Darcy PK; Kershaw MH
PLoS One; 2014; 9(5):e95847. PubMed ID: 24788789
[TBL] [Abstract][Full Text] [Related]
2. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
[TBL] [Abstract][Full Text] [Related]
4. Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.
Westwood JA; Darcy PK; Guru PM; Sharkey J; Pegram HJ; Amos SM; Smyth MJ; Kershaw MH
J Transl Med; 2010 Apr; 8():42. PubMed ID: 20426873
[TBL] [Abstract][Full Text] [Related]
5. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.
Yonezawa A; Dutt S; Chester C; Kim J; Kohrt HE
Clin Cancer Res; 2015 Jul; 21(14):3113-20. PubMed ID: 25908780
[TBL] [Abstract][Full Text] [Related]
6. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.
Dai M; Yip YY; Hellstrom I; Hellstrom KE
Clin Cancer Res; 2015 Mar; 21(5):1127-38. PubMed ID: 25142145
[TBL] [Abstract][Full Text] [Related]
7. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.
Quetglas JI; Dubrot J; Bezunartea J; Sanmamed MF; Hervas-Stubbs S; Smerdou C; Melero I
Mol Ther; 2012 Sep; 20(9):1664-75. PubMed ID: 22735380
[TBL] [Abstract][Full Text] [Related]
9. Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.
Tongu M; Harashima N; Tamada K; Chen L; Harada M
Cancer Sci; 2015 Jan; 106(1):9-17. PubMed ID: 25363339
[TBL] [Abstract][Full Text] [Related]
10. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model.
Newcomb EW; Lukyanov Y; Kawashima N; Alonso-Basanta M; Wang SC; Liu M; Jure-Kunkel M; Zagzag D; Demaria S; Formenti SC
Radiat Res; 2010 Apr; 173(4):426-32. PubMed ID: 20334514
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
Dubrot J; Palazón A; Alfaro C; Azpilikueta A; Ochoa MC; Rouzaut A; Martinez-Forero I; Teijeira A; Berraondo P; Le Bon A; Hervás-Stubbs S; Melero I
Int J Cancer; 2011 Jan; 128(1):105-18. PubMed ID: 20309938
[TBL] [Abstract][Full Text] [Related]
15. CD137, an attractive candidate for the immunotherapy of lung cancer.
Ye L; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Cancer Sci; 2020 May; 111(5):1461-1467. PubMed ID: 32073704
[TBL] [Abstract][Full Text] [Related]
16. The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII(-/-) mice.
Sallin MA; Zhang X; So EC; Burch E; Cai L; Lin W; Chapoval AI; Strome SE
Cancer Immunol Immunother; 2014 Sep; 63(9):947-58. PubMed ID: 24927849
[TBL] [Abstract][Full Text] [Related]
17. Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models.
Jang JK; Khawli LA; Canter DC; Hu P; Zhu TH; Wu BW; Angell TE; Li Z; Epstein AL
Cancer Immunol Immunother; 2016 May; 65(5):511-23. PubMed ID: 26960932
[TBL] [Abstract][Full Text] [Related]
18. Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
Kotanides H; Sattler RM; Lebron MB; Carpenito C; Shen J; Li J; Surguladze D; Haidar JN; Burns C; Shen L; Inigo I; Pennello AL; Forest A; Chen X; Chin D; Sonyi A; Topper M; Boucher L; Sharma P; Zhang Y; Burtrum D; Novosiadly RD; Ludwig DL; Plowman GD; Kalos M
Mol Cancer Ther; 2020 Apr; 19(4):988-998. PubMed ID: 32241872
[TBL] [Abstract][Full Text] [Related]
19. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.
Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Kornbluth RS
J Thorac Oncol; 2009 Jul; 4(7):802-8. PubMed ID: 19550243
[TBL] [Abstract][Full Text] [Related]
20. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.
Narazaki H; Zhu Y; Luo L; Zhu G; Chen L
Blood; 2010 Mar; 115(10):1941-8. PubMed ID: 20068221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
